2022 Q2 Form 10-Q Financial Statement

#000168875722000041 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $41.19M $38.45M $35.31M
YoY Change 28.74% 26.75% 30.98%
Cost Of Revenue $13.74M $13.52M $11.09M
YoY Change 30.5% 31.91% -10.01%
Gross Profit $27.45M $24.94M $24.23M
YoY Change 27.88% 24.12% 65.48%
Gross Profit Margin 66.65% 64.85% 68.6%
Selling, General & Admin $32.96M $26.91M $27.56M
YoY Change 51.51% 48.38% 51.42%
% of Gross Profit 120.04% 107.93% 113.75%
Research & Development $4.903M $3.598M $6.034M
YoY Change 12.74% -11.12% 34.99%
% of Gross Profit 17.86% 14.43% 24.91%
Depreciation & Amortization $950.0K $25.00K $926.0K
YoY Change 2868.75% -41.86% -23.47%
% of Gross Profit 3.46% 0.1% 3.82%
Operating Expenses $37.86M $30.51M $33.59M
YoY Change 45.05% 37.52% 48.24%
Operating Profit -$10.41M -$5.575M -$9.366M
YoY Change 124.56% 165.98% 16.78%
Interest Expense -$7.057M $2.292M -$3.727M
YoY Change -413.92% 4.42% 265.39%
% of Operating Profit
Other Income/Expense, Net -$60.00K $2.709M -$310.0K
YoY Change -103.52% -199.38% -110.73%
Pretax Income -$36.54M -$5.534M -$13.40M
YoY Change 643.63% -18.41% 117.93%
Income Tax $564.0K $399.0K $788.0K
% Of Pretax Income
Net Earnings -$37.11M -$5.933M -$14.19M
YoY Change 597.22% -14.61% 151.61%
Net Earnings / Revenue -90.08% -15.43% -40.19%
Basic Earnings Per Share -$1.52 -$0.24
Diluted Earnings Per Share -$1.521M -$0.24 -$585.6K
COMMON SHARES
Basic Shares Outstanding 24.20M shares 24.31M shares 24.00M shares
Diluted Shares Outstanding 24.40M shares 24.31M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.26M $44.66M $53.42M
YoY Change 18.82% -42.75% -36.79%
Cash & Equivalents $91.26M $44.66M $53.42M
Short-Term Investments
Other Short-Term Assets $6.634M $2.995M $2.641M
YoY Change 53.0% 13.4% 26.42%
Inventory $26.53M $28.54M $28.41M
Prepaid Expenses $2.315M
Receivables $32.00M $29.69M $24.44M
Other Receivables $0.00 $735.0K $0.00
Total Short-Term Assets $156.4M $110.0M $113.3M
YoY Change 22.04% -14.25% -14.38%
LONG-TERM ASSETS
Property, Plant & Equipment $37.38M $23.30M $18.66M
YoY Change 125.33% 42.77% 15.16%
Goodwill $465.0K $465.0K
YoY Change 0.0% 0.0%
Intangibles $4.470M $4.371M
YoY Change 8.34% 5.38%
Long-Term Investments
YoY Change
Other Assets $1.194M $1.191M $558.0K
YoY Change 93.52% 89.65% -15.96%
Total Long-Term Assets $43.46M $31.54M $26.26M
YoY Change 81.52% 31.14% 9.0%
TOTAL ASSETS
Total Short-Term Assets $156.4M $110.0M $113.3M
Total Long-Term Assets $43.46M $31.54M $26.26M
Total Assets $199.9M $141.6M $139.5M
YoY Change 31.4% -7.08% -10.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.99M $16.65M $14.48M
YoY Change 59.54% 85.13% 48.89%
Accrued Expenses $17.60M $18.06M $16.24M
YoY Change 8.78% 25.33% 11.73%
Deferred Revenue $1.266M $769.0K
YoY Change 23.63% -36.66%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.00K
YoY Change -93.5%
Total Short-Term Liabilities $34.75M $36.51M $31.89M
YoY Change 27.44% 47.02% 23.12%
LONG-TERM LIABILITIES
Long-Term Debt $145.5M $52.49M $51.91M
YoY Change 186.33% 4.34% 4.16%
Other Long-Term Liabilities $3.782M $1.821M $2.392M
YoY Change 70.44% 0.05% 2.57%
Total Long-Term Liabilities $149.3M $54.31M $54.30M
YoY Change 181.48% 4.19% 4.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.75M $36.51M $31.89M
Total Long-Term Liabilities $149.3M $54.31M $54.30M
Total Liabilities $184.0M $93.72M $88.79M
YoY Change 120.93% 17.45% 9.04%
SHAREHOLDERS EQUITY
Retained Earnings -$212.3M -$206.4M
YoY Change 23.3% 24.9%
Common Stock $221.4M $219.7M
YoY Change 2.82% 2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.854M $2.854M
YoY Change 0.0% 0.0%
Treasury Stock Shares 408.1K shares 408.1K shares
Shareholders Equity $15.87M $47.84M $50.74M
YoY Change
Total Liabilities & Shareholders Equity $199.9M $141.6M $139.5M
YoY Change 31.4% -7.08% -10.78%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$37.11M -$5.933M -$14.19M
YoY Change 597.22% -14.61% 151.61%
Depreciation, Depletion And Amortization $950.0K $25.00K $926.0K
YoY Change 2868.75% -41.86% -23.47%
Cash From Operating Activities -$11.33M -$4.840M -$7.709M
YoY Change 1285.09% -26.15% -324.75%
INVESTING ACTIVITIES
Capital Expenditures -$13.29M $798.0K -$3.615M
YoY Change 1327.39% -0.75% 219.91%
Acquisitions
YoY Change
Other Investing Activities -$525.0K $0.00 $0.00
YoY Change 13025.0% -100.0%
Cash From Investing Activities -$13.81M -$5.739M -$3.615M
YoY Change 1377.43% 274.61% 222.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.32M $1.695M 207.0K
YoY Change 17200.96% -5.1% -61.67%
NET CHANGE
Cash From Operating Activities -11.33M -$4.840M -7.709M
Cash From Investing Activities -13.81M -$5.739M -3.615M
Cash From Financing Activities 72.32M $1.695M 207.0K
Net Change In Cash 47.17M -$8.759M -11.12M
YoY Change -3633.63% 33.26% -490.07%
FREE CASH FLOW
Cash From Operating Activities -$11.33M -$4.840M -$7.709M
Capital Expenditures -$13.29M $798.0K -$3.615M
Free Cash Flow $1.959M -$5.638M -$4.094M
YoY Change 1633.63% -23.38% -189.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Country Region
CountryRegion
506
CY2022Q1 dei City Area Code
CityAreaCode
24
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
34 2400
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001688757
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#PrepaidExpenseAndOtherAssetsCurrent
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#PrepaidExpenseAndOtherAssetsCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38593
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Establishment Labs Holdings Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D8
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Building B15 and 25
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Coyol Free Zone
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Alajuela
CY2022Q1 dei Entity Address Country
EntityAddressCountry
CR
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Security12b Title
Security12bTitle
Common Shares, No Par Value
CY2022Q1 dei Trading Symbol
TradingSymbol
ESTA
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24197836 shares
CY2022Q1 us-gaap Cash
Cash
44656000 USD
CY2021Q4 us-gaap Cash
Cash
53415000 USD
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1317000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1221000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29689000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24437000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
28538000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
28407000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7133000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7012000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
110016000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
113271000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23301000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18658000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
465000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
465000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4470000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4371000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2113000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2206000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1191000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
558000 USD
CY2022Q1 us-gaap Assets
Assets
141556000 USD
CY2021Q4 us-gaap Assets
Assets
139529000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
16651000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14475000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18057000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16236000 USD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1802000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1178000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
36510000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31889000 USD
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52486000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
51906000 USD
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1099000 USD
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
703000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1805000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1900000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1821000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2392000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
93721000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
88790000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24602156 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24488335 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24194086 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24080265 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
221439000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
219737000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40018000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36584000 USD
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
408070 shares
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
408070 shares
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
2854000 USD
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2854000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212318000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206385000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1550000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3657000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
47835000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
50739000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141556000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139529000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38452000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30336000 USD
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
13516000 USD
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
10246000 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
24936000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
20090000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26913000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-158000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18138000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
941000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3598000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4048000 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
30511000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
22186000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5575000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2096000 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
2292000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
2195000 USD
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-396000 USD
CY2021Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
230000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2709000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2726000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5534000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6783000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
399000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
165000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6948000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24310856 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24310856 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23827137 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23827137 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6948000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2107000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
941000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2107000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
941000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8040000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6007000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
50739000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1702000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3434000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2107000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5933000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5933000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
47835000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74961000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1882000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1756000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
41000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6948000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
72551000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6948000 USD
CY2022Q1 esta Depreciationand Amortization Excluding Debt Discount Premium
DepreciationandAmortizationExcludingDebtDiscountPremium
953000 USD
CY2021Q1 esta Depreciationand Amortization Excluding Debt Discount Premium
DepreciationandAmortizationExcludingDebtDiscountPremium
908000 USD
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
69000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6000 USD
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
1415000 USD
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
93000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3434000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1756000 USD
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-59000 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-20000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2889000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3030000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
95000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
101000 USD
CY2022Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-396000 USD
CY2021Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
230000 USD
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
580000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
474000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5067000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5218000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
909000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
698000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-69000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1217000 USD
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
636000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-26000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2021000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-617000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1775000 USD
CY2022Q1 esta Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-91000 USD
CY2021Q1 esta Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-95000 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-181000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-221000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4840000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6554000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
798000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
804000 USD
CY2022Q1 esta Paymentsto Acquire Assets Including Receivables Held
PaymentstoAcquireAssetsIncludingReceivablesHeld
0 USD
CY2021Q1 esta Paymentsto Acquire Assets Including Receivables Held
PaymentstoAcquireAssetsIncludingReceivablesHeld
434000 USD
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
390000 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
294000 USD
CY2022Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
4551000 USD
CY2021Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5739000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1532000 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
7000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
55000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1702000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1882000 USD
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
41000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1695000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1786000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-273000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8759000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6573000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53415000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84523000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44656000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77950000 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1707000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1710000 USD
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
159000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
10000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
51000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
143000 USD
CY2022Q1 esta Noncash Consideration Payable Relatedto Asset Acquisition
NoncashConsiderationPayableRelatedtoAssetAcquisition
536000 USD
CY2021Q1 esta Noncash Consideration Payable Relatedto Asset Acquisition
NoncashConsiderationPayableRelatedtoAssetAcquisition
407000 USD
CY2022Q1 esta Number Of Manufacturing Facilities
NumberOfManufacturingFacilities
2 facility
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates and management judgments reflected in the condensed </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial statements include items such as accounts receivable valuation and allowances, inventory valuation and allowances, valuation of acquired intangible assets, valuation of derivatives and valuation of deferred income tax assets, including tax valuation allowances. Estimates are based</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on historical experience, where applicable, and other assumptions believed to be reasonable by management. Actual results may differ from those estimates under different assumptions or conditions.</span></div>
CY2021Q1 us-gaap Supplies
Supplies
577000 USD
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash and accounts receivable. The majority of the Company’s cash is held at two financial institutions in the United States. Balances in the Company’s cash accounts exceed the Federal Deposit Insurance Corporation, or FDIC, limit of $250,000. The Company has not experienced any losses to its deposits of cash.</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s revenue has been derived from sales of its products in international markets, principally Europe, the Middle East, Latin America, and Asia. In the international markets in which the Company operates, the Company uses a combination of distributors and makes direct sales to customers. The Company performs ongoing credit evaluations of its distributors and customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s revenues were derived from the sale of Motiva Implants. During the three months ended March 31, 2022 and 2021, no customer accounted for more than 10% of the Company’s revenue. No customers accounted for more than 10% of the Company’s trade accounts receivable balance as of March 31, 2022. One customer accounted for 11.8% of the Company’s trade accounts receivable balance as of </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on NuSil Technology, LLC, or NuSil, as the sole supplier of medical-grade silicone used in Motiva Implants. During the three months ended March 31, 2022 and 2021, the Company had purchases of $7.3 million, or 31.4% of total purchases, and $4.3 million, or 55.8% of total purchases, respectively, from NuSil. As of March 31, 2022 and </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an outstanding balance owed to this vendor of $2.7 million and $2.5 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of regulatory approval of the Company’s current and potential future products, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, access to capital, strategic relationships and dependence on key individuals and sole source suppliers. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products developed by the Company require clearances from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company is denied clearance, clearance is delayed, or the Company is unable to maintain its existing clearances, these developments could have a material adverse impact on the Company. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak caused a material disruption of the operations of the Company and its suppliers and customers in fiscal 2020 and, to a lesser degree, in fiscal 2021 and resulted in delayed clinical trial enrollment within the reconstruction cohort of its IDE clinical trial in the United States. However, to date, the impact from the COVID-19 outbreak has not had a material effect on the Company’s liquidity or financial position. The full extent of </span></div>any future impact of the continuing outbreak, related business and travel restrictions, and changes to behavior intended to reduce its spread is uncertain and continues to evolve globally. Management continues to monitor the impact that the COVID-19 pandemic is having on the Company, the breast aesthetics and reconstruction market and the economies in which the Company operates.
CY2022Q1 esta Number Of Financial Institutions Holding Cash
NumberOfFinancialInstitutionsHoldingCash
2 financial_institution
CY2022Q1 esta Number Of Financial Institutions Holding Cash
NumberOfFinancialInstitutionsHoldingCash
2 financial_institution
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 USD
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 USD
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2600000 USD
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1200000 USD
CY2022Q1 esta Revenue From Contract With Customer Product Return Period
RevenueFromContractWithCustomerProductReturnPeriod
P15D
CY2022Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3000 USD
CY2021Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
10000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38452000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30336000 USD
CY2022Q1 esta Revenue From Contract With Customer Product Shelf Life
RevenueFromContractWithCustomerProductShelfLife
P5Y
CY2022Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P50Y
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2022Q1 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 reportingunit
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2022Q1 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Embedded Derivatives</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting standards for derivatives and for distinguishing liabilities from equity when accounting for hybrid contracts. The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with ASC 470-20 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 6).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses option pricing valuation models to determine the fair value of embedded derivatives and records any change in fair value as a component of other income or expense in the condensed consolidated statements of operations (see Note 5).</span></div>
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
18492000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
28538000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2800000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2700000 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
19068000 USD
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7609000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
8519000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1861000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1396000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
28407000 USD
CY2022Q1 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
4200000 USD
CY2021Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
3500000 USD
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
2082000 USD
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
2315000 USD
CY2022Q1 us-gaap Supplies
Supplies
386000 USD
CY2021Q1 us-gaap Prepaid Taxes
PrepaidTaxes
551000 USD
CY2022Q1 esta Prepaid Warranty And Distribution Rights Current
PrepaidWarrantyAndDistributionRightsCurrent
174000 USD
CY2021Q1 esta Prepaid Warranty And Distribution Rights Current
PrepaidWarrantyAndDistributionRightsCurrent
516000 USD
CY2022Q1 esta Prepaid Clinical Trial Costs Current
PrepaidClinicalTrialCostsCurrent
761000 USD
CY2021Q1 esta Prepaid Clinical Trial Costs Current
PrepaidClinicalTrialCostsCurrent
412000 USD
CY2022Q1 us-gaap Prepaid Taxes
PrepaidTaxes
735000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2995000 USD
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2641000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7133000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7012000 USD
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35835000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30548000 USD
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12534000 USD
CY2021Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1400000 USD
CY2021Q1 esta Depreciation And Amortization Property Plant And Equipment
DepreciationAndAmortizationPropertyPlantAndEquipment
600000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11890000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23301000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18658000 USD
CY2022Q1 esta Depreciation And Amortization Property Plant And Equipment
DepreciationAndAmortizationPropertyPlantAndEquipment
600000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1400000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
25000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
43000 USD
CY2022Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4495000 USD
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3346000 USD
CY2022Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4342000 USD
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3904000 USD
CY2022Q1 esta Accrued Stock Option Grant Bonus Current
AccruedStockOptionGrantBonusCurrent
5968000 USD
CY2021Q4 esta Accrued Stock Option Grant Bonus Current
AccruedStockOptionGrantBonusCurrent
5570000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
405000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
402000 USD
CY2022Q1 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
951000 USD
CY2021Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1138000 USD
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
914000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
819000 USD
CY2022Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
170000 USD
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
167000 USD
CY2022Q1 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
0 USD
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
137000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
812000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
753000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18057000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16236000 USD
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1266000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
769000 USD
CY2022Q1 esta Cash Payable For Asset Acquisition Current
CashPayableForAssetAcquisitionCurrent
536000 USD
CY2021Q4 esta Cash Payable For Asset Acquisition Current
CashPayableForAssetAcquisitionCurrent
409000 USD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1802000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1178000 USD
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1821000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2392000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
465000 USD
CY2022Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 USD
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2022Q1 us-gaap Goodwill
Goodwill
465000 USD
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
291000 USD
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
291000 USD
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8795000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4325000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4470000 USD
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
291000 USD
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
291000 USD
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8412000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4041000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4371000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
25000 USD
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
35000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
902000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
931000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
857000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
689000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
403000 USD
CY2022Q1 esta Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
397000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4179000 USD
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
147000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
167000 USD
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 USD
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000 USD
CY2022Q1 us-gaap Lease Cost
LeaseCost
26000 USD
CY2021Q1 us-gaap Lease Cost
LeaseCost
38000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2113000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2206000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
405000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
402000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1805000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1900000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2210000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2302000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
187000 USD
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
154000 USD
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
12000 USD
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
13000 USD
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
30000 USD
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 USD
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
42000 USD
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
13000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.082
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
147000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
160000 USD
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1000 USD
CY2021Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
7000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
55000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
36000 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
416000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
14000 USD
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24602156 shares
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
535000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
9000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
504000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
9000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
429000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
9000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
404000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
9000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
436000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2724000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
50000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
514000 USD
CY2022Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
8000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2210000 USD
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
42000 USD
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24488335 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24194086 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24080265 shares
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5389478 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4549256 shares
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1757000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
33.02
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2098087 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
37.49
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
67357000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
45.54
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11045 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.44
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
113821 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.96
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
39192 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1956119 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.87
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
60107000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
894656 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
21.26
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
41500000 USD
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
113821 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.96
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7300000 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
24800000 USD
CY2022Q1 esta Employee And Non Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Notyet Recognized Periodfor Recognition
EmployeeAndNonEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotyetRecognizedPeriodforRecognition
P2Y3M18D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.007
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6948000 USD
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24310856 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24310856 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23827137 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23827137 shares
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1795144 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1949010 shares

Files In Submission

Name View Source Status
0001688757-22-000041-index-headers.html Edgar Link pending
0001688757-22-000041-index.html Edgar Link pending
0001688757-22-000041.txt Edgar Link pending
0001688757-22-000041-xbrl.zip Edgar Link pending
esta-20220331.htm Edgar Link pending
esta-20220331.xsd Edgar Link pending
esta-20220331_cal.xml Edgar Link unprocessable
esta-20220331_def.xml Edgar Link unprocessable
esta-20220331_htm.xml Edgar Link completed
esta-20220331_lab.xml Edgar Link unprocessable
esta-20220331_pre.xml Edgar Link unprocessable
exhibit103q12022.htm Edgar Link pending
exhibit104q12022.htm Edgar Link pending
exhibit311q12022.htm Edgar Link pending
exhibit312q12022.htm Edgar Link pending
exhibit321q12022.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
s-a2xelxnusilamend2to2016s.jpg Edgar Link pending
s-a3xelxnusilamend3to2016s.jpg Edgar Link pending
Show.js Edgar Link pending